• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The anticoagulation dilemma and future treatment avenues in patients with breast cancer and atrial fibrillation
Atrial fibrillation (AF) is the most common arrhythmia, with a substantial rise in global incidence and prevalence. Ischemic stroke is a frequent complication of AF, since AF perfectly fulfills Virchow's triad of blood stasis, vascular damage and hypercoagulation, making oral anticoagulation (OAC) obligatory for stroke prevention. Direct oral anticoagulants (DOAC), such as dabigatran, which inhibits thrombin, and apixaban, edoxaban and rivaroxaban, which block the activated coagulation factor X (FXa), have some advantages and are largely replacing coumarin-based OAC.
Source: International Journal of Cardiology - September 30, 2020 Category: Cardiology Authors: Anke C. Fender, Dobromir Dobrev Tags: Editorial Source Type: research

Direct oral anticoagulants in the prevention of stroke in breast cancer patients with atrial fibrillation during adjuvant endocrine therapy: A cohort study
Atrial fibrillation (AF) is a frequent comorbidity in malignant patients. Anticancer therapies complicate anticoagulant strategy. We evaluated the safety and efficacy of long-term use of direct oral anticoagulants (DOACs) in breast cancer women.
Source: International Journal of Cardiology - September 11, 2020 Category: Cardiology Authors: Renata Pacholczak-Madej, Stanis ława Bazan-Socha, Lech Zaręba, Anetta Undas, Jerzy Dropiński Source Type: research